- citati u SCIndeksu: 0
- citati u CrossRef-u:0
- citati u Google Scholaru:[
 ]
- posete u poslednjih 30 dana:7
- preuzimanja u poslednjih 30 dana:5
|
|
|
2018, vol. 5, br. 3, str. 687-693
|
|
Prevalencija dijabetes melitusa i upotreba antidijabetičnih lekova u istočnoj Bosni i Hercegovini - pilot studija
Prevalence of diabetes mellitus and antidiabetic drug utilization in the Eastern Bosnia and Herzegovina: A pilot study
aHealth Institution Moja apoteka, Foča, Bosnia and Herzegovina bUniverzitet u Novom Sadu, Medicinski fakultet, Katedra za farmakologiju i toksikologiju
e-adresa: olga.horvat@mf.uns.ac.rs
Projekat: Interakcije ksenobiotika i uticaj na sisteme u biomedicini (MPNTR - 41012)
Sažetak
Ne postoje kompletirani nacionalni podaci o prevalenciji dijabetes melitusa (DM) u Bosni i Hercegovini (BiH), a jedini dostupni podaci nastali su ekstrapolacijom podataka iz susednih zemalja. Ovo istraživanje studija imalo je za cilj da utvrdi prevalencuiju DM, kao i upotrebu antidijabetičkih lekova (AD) i stopu izloženosti pacijenata sa DM AD u istočnom regionu Republike Srpske (RS), BiH. Podaci o upotrebi upoređeni sa podacima iz Srbije, Mađarske i Norveške. Podaci o broju svih odraslih pacijenata sa DM tipovima 1 i 2 u tri opštine u istočnom regionu RS dobijeni su iz medicinske dokumentacije. Upotreba AD u RS, Srbiji, Mađarskoj i Norveškoj za 2013. godinu analizirana je primenom ATC/DDD metodologije. Izloženost pacijenata sa DM AD izražena je u procentima. Zabeležena prevalencija DM u tri posmatrane opštine iznosila je 6,65%, sa visokim udelom tipa 1 u poređenju sa tipom 2 DM (25,32% do 74,68%). Ukupna potrošnja AD zabeležena u našem ispitivanju studiji bila je slična upotrebi u Norveškoj, ali niža nego u Srbiji i Mađarskoj. Procenat teorijske izloženosti svakog pacijenta AD iznosio je samo 78,24%, slično izloženosti u Srbiji (80,6%), dok su Norveška a posebno Mađarska imali izuzetno visoku izloženost (103,8 i 126,5%). Visoki procenat pacijenata sa tip 1 DM zabeleženih u našoj studiji ukazuje na nedovoljno otkrivanje DM, posebno tipa 2, dok je niska stopa izloženosti pacijenata sa DM AD ukazuje na to da su čak i registrovani pacijenti sa DM nedovoljno lečeni. Postoji hitna potreba za intervencijama u prevenciji i lečenju DM u BiH.
Abstract
There are no national estimates for the prevalence of DM in Bosnia and Herzegovina (BiH), available data is extrapolated from neighboring countries. This study aimed to determine the prevalence of DM, as well as utilization of antidiabetic drugs (ADs) and exposure rates of DM patients to ADs in the eastern region of the Republic of Srpska (RS), BiH. For external reference, data were compared to that from Serbia, Hungary and Norway. Data on the number of all adult patients with DM type 1 and 2 in the three municipalities in the eastern region of RS were obtained from medical records. The use of ADs in the RS, Serbia, Hungary and Norway for the year of 2013 was analysed by ATC/Defined Daily Dose methodology. The exposure of DM patients to ADs was expressed in percentage. The recorded DM prevalence in the three observed municipalities was 6.65%, with high proportion of type 1 compared to type 2 DM (25.32% to 74.68%). The total consumption of ADs recorded in our study was similar to those in Norway, but lower than in Serbia and Hungary. The percentage of theoretical exposure of each patient to ADs was only 78,24%, similar to that in Serbia (80.6%), whereas Norway and especially Hungary had exceptionally good exposure rates (103,8 and 126.5%). High proportion of type 1 DM patients recorded in our study indicates the insufficient detection of DM, especially type 2, whereas the low exposure rate of patients with DM to ADs indicates that even the registered patients with DM are undertreated. There is an urgent need for interventions in prevention and treatment of DM in BiH.
|
|
|
|
Reference
|
|
|
Agency for Statistics of Bosnia and Herzegovina (2016) Census of population, households and dwellings in Bosnia and Herzegovina: 2013 final results. Sarajevo, Available at: http://www.popis2013.ba/popis2013/doc/Popis2013prvoIzdanje.pdf [Accessed 28 Nov, 2016]
|
|
  
|
Berg, T.J. (2013) National diabetes strategy and diabetes epidemiology in Norway. Norsk Epidemiologi, 23(1):
|
|
|
de Pablos, V.P., Franch, J., Banegas, B.J.R., Fernández, A.S., Sicras, M.A., Díaz, C.S. (2009) Estudio epidemiológico del perfil clínico y control glucémico del paciente diabético atendido en centros de atención primaria en España (estudio EPIDIAP). Endocrinología y Nutrición, 56(5): 233-240
|
|
|
Doró, P., Benkő, R., Kosik, E., Matuz, M., Tóth, K., Soós, G. (2005) Utilization of oral antihyperglycemic drugs over a 7-year period (1998-2004) in a Hungarian population and adherence to drug therapy. European Journal of Clinical Pharmacology, 61(12): 893-897
|
|
|
Fabian, W., Majkowska, L., Stefański, A., Moleda, P. (2005) Prevalence of diabetes, antidiabetic treatment and chronic diabetic complications reported by general practitioners. Przegl Lek., 62(4): 201-5
|
|
1
|
Gikas, A., Sotiropoulos, A., Panagiotakos, D., Peppas, T., Skliros, E., Pappas, S. (2004) Prevalence, and associated risk factors, of self-reported diabetes mellitus in a sample of adult urban population in Greece: Medical exit poll research in Salamis (MEDICAL EXPRESS 2002). BMC Public Health, 4:2, Available from: http://www.biomedcentral.com/1471-2458/4/2
|
|
|
Institut za javno zdravstvo Republike Srpske (2014) Izvjestaj o potrosnji i prometu gotovih lijekova u Republici Srpskoj u 2013. godini. Banja Luka
|
|
3
|
International Diabetes Federation (2013) IDF diabetes atlas. 6th ed
|
|
|
Jenum, A.K., Lorentzen, C., Anderssen, S.A., Birkeland, K.I., Holme, I., Lund-Larsen, P.G., Ommundsen, Y., Raastad, T., Thelle, D.S., Bahr, R. (2003) Promoting physical activity in a multi-ethnic district - methods and baseline results of a pseudo-experimental intervention study. European Journal of Cardiovascular Prevention & Rehabilitation, 10(5): 387-396
|
|
|
Jermendy, G., Nádas, J., Szigethy, E., Széles, G., Nagy, A., Hídvégi, T., Paragh, G., Ádány, R. (2010) Prevalence Rate of Diabetes Mellitus and Impaired Fasting Glycemia in Hungary: Cross-Sectional Study on Nationally Representative Sample of People Aged 20-69 Years. Croatian Medical Journal, 51(2): 151-156
|
|
|
Mandolfi, F., Frascio, M., Perotti, S., Lazzara, F., Imperatore, M., Bruno, S. (2013) Diabetes Mellitus and upper gut motility. J Biol Res., 86(1): 25-8
|
|
|
Matelko, Z., Granic, M., Skrabalo, Z. (2003) Secerna bolest. u: Vrhovac B. [ur.] Interna Medicina, Zagreb: Naprijed, 1264-84
|
|
|
Metelko, Ž., Pavlić-Renar, I., Poljičanin, T., Szirovitza, L., Turek, S. (2008) Prevalence of diabetes mellitus in Croatia. Diabetes Research and Clinical Practice, 81(2): 263-267
|
|
|
Mladenović, V., Pantović, V., Djukić, A., i dr. (2008) Epidemiological characteristics of diabetic patients in Kragujevac. Medi Čas (Krag), 42(2): 07-12
|
|
|
Mota, M., Popa, S.G., Mota, E., i dr. (2016) Prevalence of diabetes mellitus and prediabetes in the adult Romanian population: PREDATORR study. J Diabetes, May; 8(3): 336-44
|
|
|
Murray, C.J.L., Vos, t L.A.D., i dr. (2015) Global, regional, and national disability-adjusted life years (DALYs) for 306 diseases and injuries and healthy life expectancy (HALE) for 188 countries, 1990-2013: quantifying the epidemiological transition. Lancet, 386 (10009): 2145-91
|
|
|
Murray, C.J.L., Vos, t L.A.D., i dr. (2015) Global, regional, and national age-sex specifi c all-cause and cause-specifi c mortality for 240 causes of death, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet, 385(9963): 117-71
|
|
|
Olsson, J., Tollin, C., Nilsson, S., Melander, A. (1994) Intercommunity variations in antidiabetic drug utilization and in prevalence of diabetes mellitus. Pharmacoepidemiology & Drug Safety, 3(4): 215-221
|
|
|
Radonjić, V., Đukić, Lj. (2012) Trade and consumption of the medicinal products: Annual reports 2013. Belgrade: Medicines and Medical Devices Agency of Serbia, hard copy in Serbian language
|
|
|
Sakshaug, S., ur. (2014) Drug Consumption in Norway 2009-2013(Legemiddelforbruket i Norge 2009-2013). Oslo: Norwegian Institute of Public Health(legemiddelstatistikk), 1. Available at: http://www.fhi.no/dokumenter/6f9b71d72a.pdf [Accessed 05 August 2013]
|
|
|
Stanković, Ž., Jašović-Gašić, M., Lečić-Toševski, D. (2013) Psychological problems in patients with type 2 diabetes: Clinical considerations. Vojnosanitetski pregled, vol. 70, br. 12, str. 1138-1144
|
|
|
The hypertension in Diabetes Study Group (1993) Hypertension in Diabetes Study (HDS): II. Increased risk of cardiovascular complications in hypertensive type 2 diabetic patients. J Hypertens, 11(3):319-25
|
|
|
Vamos, E.P., Kopp, M.S., Keszei, A., Novak, M., Mucsi, I. (2008) Prevalence of diabetes in a large, nationally representative population sample in Hungary. Diabetes Research and Clinical Practice, 81(3): e5-e8
|
|
|
Winkler, G., Hídvégi, T., Vándorfi, G., Balogh, S., Jermendy, G. (2013) Prevalence of undiagnosed abnormal glucose tolerance in adult patients cared for by general practitioners in Hungary. Results of a risk-stratified screening based on FINDRISC questionnaire. Medical Science Monitor, 19: 67-72
|
|
1
|
World Health Organization (2003) Diet, nutrition and the prevention of chronic diseases: Report of a Joint WHO/FAO Expert Consultation. WHO technical Report Series, Geneva, 916
|
|
|
World Health Organization-Collaborating Centre for Drug Statistics Metodology About the ATC/DDD system. Available from: http:// www.whocc.no/ atcddd/. [Accessed 28 Sep, 2016]
|
|
|
|
|